Best Practices for Long-Term Monitoring and Follow-Up of Alemtuzumab-Treated MS Patients in Real-World Clinical Settings

Best Practices for Long-Term Monitoring and Follow-Up of Alemtuzumab-Treated MS Patients in Real-World Clinical Settings

Multiple sclerosis (MS) is a chronic autoimmune neurological disease that typically affects young adults, causing irreversible physical disability and cognitive impairment. Alemtuzumab, administered intravenously as 2 initial courses of 12 mg/day (5 consecutive days at baseline, and 3 consecutive da...

Full description

Bibliographic Details
Main Authors: Krista Barclay, Robert Carruthers, Anthony Traboulsee, Ann D. Bass, Christopher LaGanke, Antonio Bertolotto, Aaron Boster, Elisabeth G. Celius, Jérôme de Seze, Dionisio Dela Cruz, Mario Habek, Jong-Mi Lee, Volker Limmroth, Sven G. Meuth, Celia Oreja-Guevara, Patricia Pagnotta, Cindy Vos, Tjalf Ziemssen, Darren P. Baker, Bart Van Wijmeersch
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-03-01
Series:Frontiers in Neurology
Subjects:
relapsing-remitting multiple sclerosis
disease-modifying therapy
alemtuzumab
anti-CD52 monoclonal antibody
monitoring
autoimmune events
Online Access:https://www.frontiersin.org/article/10.3389/fneur.2019.00253/full

Internet

https://www.frontiersin.org/article/10.3389/fneur.2019.00253/full

Similar Items